Financial Results Nine Months 2020

Financial Results Nine Months 2020

Pillars of growth

R&D

Heavy bet for R&D
as a future
growth engine

conocer +

R&D&i
R&D

Heavy bet on R&D
as a future
growth engine

find out more

R&D&i
Biosimilar de Enoxaparina

Biosimilars

A great growth opportunity for ROVI in a market that totals more than 1,000 million euros in Europe.

find out more

Especialidades farmacéuticas

Pharmaceutical products

Diversified portfolio of innovative own and licensed products protected by patents.
 

find out more

Bemiparina

Low Molecular Weight Heparin

ROVI's principal product, a low-molecular-weight heparin developed in-house.
 

find out more

Fabricación a terceros

Contract manufacturing

High production capacity with four manufacturing plants for prefilled syringes and oral solid forms.

find out more

Rovi en cifras

Rovi in figures

+119%

Net profit of the businessin 2019

+46%

2019 LMWHglobal sales

65 countries

LMWH presence through strategic alliances with international partners

6 plants

for manufacturing own and third-party products in Spain

€29,3 Mn

of investment in R&D in 2019 Commitment to innovation

7 countries

Direct presence through subsidiaries  to market Enoxaparin

Information for investors

Detailed information for investors and shareholders. All of ROVI’s information, results and figures presented clearly and transparently.

Go to Shareholders and Investors

 

Last news on Rovi 

(See all items)

0

27/11/2020

The Journal npj Schizophrenia Publishes the Results of the PRISMA-3 Study of the Efficacy and Safety of Doria® in Schizophrenic Patients

The results of the phase III pivotal clinical trial show that the once-monthly injectable antipsychotic Doria® furnishes a significant improvement in the symptomatology and severity of the illness in patients with acute exacerbation of schizophrenia.

0

24/11/2020

2020 Capital Markets Day presentation

ROVI updates its strategy in a meeting with shareholders, investors and analysts.

Last annual report

annualreport1

Annual Report 2019

Last regular
public information

annualreport1

Executive Summary